NCT02414347 F 18 T807 Tau PET Imaging of Alzheimer's Disease
| NCT ID | NCT02414347 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tammie L. S. Benzinger, MD, PhD |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2014-10-23 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900 participants in total. It began in 2014-10-23 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.
Eligibility Criteria
Inclusion Criteria: 1. Male or female participants, at least 18 years of age. 2. Cognitively normal, or with mild dementia, as assessed clinically 3. Participant is able and willing to undergo testing (MRI or CT, PET, radioactive tracer injection, LP; for those unable to undergo an MRI, CT will be used to generate regions-of-interest). 4. Pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug administration. Exclusion Criteria: 1. Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with severe chronic back pain might not be able to lie still during the scanning procedures). 2. Is deemed likely unable to perform the imaging procedures for any reason. 3. Has a high risk for Torsades de Pointes or is taking medications known to prolong QT interval. 4. Has hypersensitivity to F 18 T807 or any of its excipients. 5. Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate. 6. Severe claustrophobia. 7. Currently pregnant or breast-feeding. 8. For those electing to undergo the optional lumbar puncture: currently on anticoagulant of any form -
Contact & Investigator
Tammie Benzinger, MD, PhD
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT02414347 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02414347 currently recruiting?
Yes, NCT02414347 is actively recruiting participants. Contact the research team at kelleyj@wustl.edu for enrollment information.
Where is the NCT02414347 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT02414347 clinical trial?
NCT02414347 is sponsored by Tammie L. S. Benzinger, MD, PhD. The principal investigator is Tammie Benzinger, MD, PhD at Washington University School of Medicine. The trial plans to enroll 900 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.